These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 23855420

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A, Bailey C, Abdelhafiz AH.
    Age Ageing; 2012 Sep 01; 41(5):681-4. PubMed ID: 22378612
    [Abstract] [Full Text] [Related]

  • 45. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
    Szapary L, Fehér G, Bosnyák E, Deli G, Csécsei P.
    Ideggyogy Sz; 2013 May 30; 66(5-6):165-74. PubMed ID: 23909016
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
    Lewalter T.
    MMW Fortschr Med; 2012 Mar 22; 154(5):50-2, 54. PubMed ID: 22624265
    [No Abstract] [Full Text] [Related]

  • 48. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L, RE-LY Investigators.
    J Am Coll Cardiol; 2014 Feb 04; 63(4):321-8. PubMed ID: 24076487
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Panchenko EP.
    Kardiologiia; 2011 Feb 04; 51(11):83-90. PubMed ID: 22117775
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
    Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S.
    Thromb Haemost; 2014 May 05; 111(5):933-42. PubMed ID: 24326736
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Intracranial hemorrhage during dabigatran treatment.
    Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, Kameda K, Shono T, Nagata S, Ago T, Kitazono T, Okada Y.
    Circ J; 2014 May 05; 78(6):1335-41. PubMed ID: 24662438
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P.
    MMW Fortschr Med; 2013 May 16; 155(9):20. PubMed ID: 23951642
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.